Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

New Medidur inserter sees positive response
September 2016
SHARING OPTIONS:

WATERTOWN, Mass.—pSivida Corp.’s recent utilization study of its proprietary 27-gauge inserter for Medidur for posterior uveitis—a chronic, non-infectious inflammatory disease affecting the posterior segment of the eye and a leading cause of blindness—reached its primary endpoint. Medidur is an injectable micro-insert that is implanted into the back of the eye and dispenses a sustained release of the corticosteroid fluocinolone acetonide to the retina for three years. The study sought to determine the utilization and safety of the inserter and insert, with a primary endpoint of a proportionate rating of procedures as routine or higher for the 27-gauge inserted compared to the 25-gauge model. Sixty-six percent of injections in the study achieved a satisfactory rating of “Routine,” “Easy” or “Very Easy,” compared to 46 percent of such responses for the 25-gauge inserter.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.